

Cumulative Compound Index

September 2002—August 2003

[Volume 45, Part 10—Volume 46, Part 9 *inclusive*]

Compound	Year	Vol	Part	Pages
A				
A77 1726, [C-13(4)]	2003	46	7	613–622
Abscisic acid, [H-2]-labelled	2003	46	3	273–283
ABT-770, [C-14]	2003	46	9	883–892
<i>N</i> -Acetyl-(<i>S</i> -farnesyl)-cysteine, [35-S]- <i>N</i> -methane sulfonyl, and methyl ester	2003	46	1	29–54
<i>N</i> -(4-Acetyl-1-piperazinyl)-4-fluorobenzamide, [F-18]	2002	45	14	1219–1228
Adenosine analogues, [F-18]-labelled	2003	46	9	805–814
Agrochemicals, [C-14]-labelled, storage of	2003	46	3	211–220
Alkyl-nucleosides, -nucleotides, and -bases, [H-3]-labelled	2003	46	9	815–835
AM694, regioselective [F-18]-labelled	2003	46	9	799–804
2-Aminoacetaldehyde dimethylacetal, [N-15]	2002	45	12	1055–1064
2-Amino-[(2-H-2(2))-acetaldehyde] diethyl acetal	2002	45	12	1055–1064
(<i>1R,2S</i>)-2-Amino-1-(3-benzyloxy-4-[[C-11]-methyl]-phenyl)-1-propanol, <i>also</i> 4-methyl-metaraminol, [C-11]	2003	46	1	55–65
2-Aminoethylcarbamic acid, <i>t</i> -butyl ester, [1,2-H-2(4)]	2002	45	11	899–909
<i>N</i> -([1,2-H-2(4)]-2-Aminoethyl)guanidine hydrochloride	2002	45	11	899–909
2-Aminoimidazole, [C-13(1); N-15(3)]	2002	45	12	1055–1064
2-Aminoimidazole hydrochloride, [C-13(1); H-2(1); N-15(2)]	2002	45	12	1055–1064
5-Aminoimidazole-4-carboxamide ribonucleosides, [P-32]-phosphorylation of,	2002	45	13	1097–1102
<i>N</i> -[5-[[[(2-[[[(2-[(Aminoiminomethyl)amino]ethyl)amino]-carbonyl]-1-methyl-1 <i>H</i> -pyrrol-3-yl]-4-amino]carbonyl]-1-methyl-1 <i>H</i> -pyrrol-3-yl]-4-[[[4-[(2-bromo-1-oxo-2-propenyl)amino]-1-methyl-1 <i>H</i> -pyrrol-2-yl]carbonyl]-amino]-1-methyl-1 <i>H</i> -pyrrole-2-carboxamide hydrochloride, <i>see also</i> Brostallicin, PNU-166196A	2002	45	11	899–909

Compound	Year	Vol	Part	Pages
<i>N</i> -(5-{{[(5-{{[(2-(Aminoiminomethyl)amino]([1,2-H-2(4)]-ethyl)amino]carbonyl]-1-methyl-1 <i>H</i> -pyrrol-3-yl]amino]-carbonyl]-1-methyl-1 <i>H</i> -pyrrol-3-yl]-1-methyl-4-nitro-1 <i>H</i> -pyrrole-2-carboxamide hydrochloride	2002	45	11	899–909
<i>N</i> -(5-[2-(Aminoiminomethyl)amino]([1,2-H-2(4)]-ethyl) amino]carbonyl]-1-methyl-1 <i>H</i> -pyrrol-3-yl)-1-methyl-4-nitro-1 <i>H</i> -pyrrole-2-carboxamide hydrochloride	2002	45	11	899–909
<i>N</i> -(2-{{[Amino(imino)methyl]amino}([1,2-H-2(4)]-ethyl)-1-methyl-4-nitro-1 <i>H</i> -pyrrole-2-carboxamide hydrochloride	2002	45	11	899–909
2-Amino-6- <i>O</i> -[[[C-11]-methoxymethyl]benzyloxy]-9-benzyl purines	2002	45	14	1239–1252
2-Amino-8-[2-(3-{{(2 <i>R</i>)-2-methylpiperazinyl}-2-pyrazinyloxy}][<i>U</i> -C-14]ethoxy]quinoline, <i>also</i> PNU-243922, [C-14]	2003	46	1	85–92
2-Amino-8-[2-(3-{{(2 <i>R</i>)-2-methyl-4-(triphenylmethyl)-piperazinyl}-2-pyrazinyloxy}][<i>U</i> -C-14]ethoxy]quinoline	2003	46	1	85–92
Arachidonic acid, [5,6,8,9,11,12,14,15-H-3(8)] and derived amides	2003	46	2	187–193
Arg ³⁴ Lys ²⁶ (<i>N</i> ^ε - γ -L-glutamyl(<i>N</i> ^z -palmitoyl))-GLP—1(7-37) <i>see</i> NN2211	2003	46	6	499–510
3'-Azido-3'-deoxythymidine, [H-3]	2003	46	7	669–676
B				
Befloxatone, [C-11]	2003	46	9	783–792
8-(3-Benzoylbenzyloxy)- <i>S</i> -[3,7-dimethyl-(<i>E,E</i>)-octa-2,6-dien-1-yl]- <i>N</i> -[[S-35]-methanesulfonyl]-cysteine, and Me ester	2003	46	1	29–54
2-(4-{{Benzyl((-)-(2 <i>R</i>)-6-acetoxy-3,4-dihydro-2 <i>H</i> -[4-C-14]-chromen-2-ylmethyl)amino}butyl)-1,1-dioxo-1,2-benzisothiazole-3(2 <i>H</i>)-one	2002	45	13	1115–1132
2-(4-{{Benzyl((-)-(2 <i>R</i>)-6-acetyl-3,4-dihydro-2 <i>H</i> -[4-C-14]-chromen-2-ylmethyl)amino}butyl)-1,1-dioxo-1,2-benziso-thiazole-3(2 <i>H</i>)-one	2002	45	13	1115–1132
(-)-(2 <i>R</i>)-2-(Benzylaminomethyl)-[4-C-14]-chromane	2002	45	13	1115–1132
2-(4-{{Benzyl((-)-(2 <i>R</i>)-3,4-dihydro-2 <i>H</i> -[4-C-14]-chromen-2-ylmethyl)amino}butyl)-1,1-dioxo-1,2-benzisothiazole-3(2 <i>H</i>)-one	2002	45	13	1115–1132
2-(2-Benzoyloxy-6-nitrophenyl)-acetonitrile, [1-C-14]	2002	45	13	1143–1152
BF-108, [F-18]	2003	46	8	765–772
BIIL 260, [H-3(2)] and [H-3(4)]	2003	46	3	221–230
Brassinolide, [26,26,26,28,28-H-3(6)]	2003	46	3	231–242
4-Bromo-3-carbomethoxypyrazine, Halex reactions upon derivs to give 4-[F-18] analogs	2003	46	1	93–98
1-Bromo-2-deoxy-2-fluoro-3,5-di- <i>O</i> -benzoyl- α -D-arabinofuranose, [F-18]	2003	46	4	285–289

Compound	Year	Vol	Part	Pages
5-(2-Bromoethyl)-2'-deoxyuridine, [Br-80 m]	2003	46	5	421–439
6-(3-Bromopropoxy)-7-propyl-3-trifluoromethyl-benzisoxazole, [5-H-3(1)]	2003	46	5	459–464
5-(2-Bromovinyl)-2'-deoxyuridine, [Br-80 m]	2003	46	5	421–439
Brostallicin, [C-14]	2002	45	11	899–909
Brostallicin, [H-2(4)]	2002	45	11	899–909
1-Butyl-3-methylimidazolium ⁺ PF ₆ ⁻ in Ir(I) catd. H-isotope exchange	2003	46	5	489–498
C				
Carbon dioxide, [C-11]	2003	46	1	55–65
Carfentanil, [C-11], h.s.a.	2003	46	9	837–842
β-Carotene, [11,12-H-3(2)]				
Castasterone, [26,26,26,28,28-H-3(6)]	2003	46	3	231–242
Catechol, [C-13] and [C-14], erratum correction	2003	46	8	781
CGS 25966, [C-11]	2003	46	4	343–351
2-(4-Chlorophenoxy)acetonitrile, [1-C-14]	2002	45	13	1143–1152
4-[4-[2-[2-[bis-(4-Chlorophenyl)methoxy]ethyl-sulfonyl]-ethoxy-[1-C-14(1)]phenyl]-1,1,1-trifluoro-2-butanone	2003	46	2	167–174
3-Chloro-4-(3-(7-propyl-3-trifluoromethyl)-[5-H-3(1)]-benzisoxazol-6-oxy)-propylsulphonyl-phenylacetic acid	2003	46	5	459–464
[4-C-14]-Chroman-2-carboxylic acid, Me ester; and (-)-(2R) enantiomer	2002	45	13	1115–1132
(-)-(2R)-[4-C-14]-Chroman-2-carboxylic acid, benzylamide	2002	45	13	1115–1132
Coenzymes, [H-3]-labelled	2003	46	5	465–473
Coenzyme Q ₁₀ , [3'-C-14]	2002	45	10	823–829
Coenzyme Q ₁₀ , [1',2-H-2(5)]	2002	45	10	831–839
CPTA-oligonucleotides, [Tc-99 m]-labelling	2003	46	2	175–186
2-Cyano-3-hydroxy-N-(4-trifluoromethylphenyl)-2-butenamide, [C-13(4)]	2003	46	7	613–622
Cyclopropylcarboxylic acid, [2-C-13]	2002	45	10	813–822
8-Cyclopropyl-3-(3-fluoropropyl)-1-([2,3-H-3(2)]-propyl)-xanthine	2003	46	4	365–372
N-([2-C-13]Cyclopropyl)-4-phenyl-1,2,3,6-tetrahydropyridine, [2-C-13]	2002	45	10	813–822
D				
2'-Deoxy-2'-fluoro-1-β-D-arabinofuranosyluracil, [F-18]	2003	46	4	285–289
1-(2'-Deoxy-2'-fluoro-β-D-arabinofuranosyl-5-(methyl-[C-11])-thymine	2003	46	3	263–272
R-(-)-Deprenyl, [C-11]	2002	45	10	803–811
2-Desoxoparaherquamide A, [14-CD ₃]	2002	45	14	1209–1218
Dextromethorphan, [18-H-2(3)]	2002	45	13	1153–1158

Compound	Year	Vol	Part	Pages
4,4'-Diaminodiphenyl sulfone, deuteriated	2003	46	2	107-114
(<i>1R,2S</i>)-2- <i>N,N</i> -Dibenzylamino-1-(3-benzyloxy-4-{[C-11]-methyl}phenyl)-1-propanol	2003	46	1	55-65
5,7-Dichloro-4-{3-(4-[4-{2-fluoroethyl}piperazin-1-yl]phenyl)ureido}-1,2,3,4-tetrahydroquinoline-2-carboxylic acid, [F-18]	2003	46	7	645-659
Digeranyl, [8-H-3(1)]	2003	46	5	401-409
2-(4-(((2 <i>R</i>)-3,4-Dihydro-2 <i>H</i> -[U-C-14]-chromen-2-yl-methyl)-((<i>1R</i>)-1-phenylethyl)amino)butyl)-1,1-dioxo-1,2-benzisothiazol-3(2 <i>H</i>)-one	2002	45	13	1115-1132
4,4'-Dimethoxydiphenyl sulfone, deuteriated	2003	46	2	107-114
<i>N</i> -(2,2-Dimethoxyethyl)-phthalimide, [N-15]	2002	45	12	1055-1064
2,3-Dimethoxy-5-([H-2(3)]methyl)-1,4-benzoquinone	2002	45	10	831-839
1-(3,5-Dimethoxyphenyl)-pentanes, [5,5,5-H-2(3) or 4,4,5,5,5-H-2(5)]	2002	45	12	1065-1076
4,4'-Di(methylamino)diphenyl sulfone, deuteriated	2003	46	2	107-114
<i>O</i> -(2-Dimethylaminoethyl)-1-(4-fluorophenyl)-3-(4-hydroxyphenyl)prop-2-enone oxime, [2-H-2(1)] and [6'-H-2(1)]	2003	46	6	531-537
3-Dimethylamino-1-phenylprop-2-enone, [2,2',6'-H-2(3)]	2003	46	6	531-537
Dimethylarsenic(V) acid. [C-14(2)], Na salt	2003	46	4	373-377
<i>N</i> -[(1,1-Dimethylethoxy)carbonyl]-4-benzyloxy-3-([H-2(3)]-methoxy)-phenylalanine	2003	46	5	389-394
<i>N</i> -[(1,1-Dimethylethoxy)carbonyl]-3-formyl-4-([H-2(3)]-methoxy)-phenylalanine	2003	46	5	389-394
4-(3,5-Dimethylhept-3-yl)-phenol, [U-C-14]	2002	45	14	1253-1263
2,2-Dimethyltetralone, [1'-C-13(1)]	2002	45	11	917-926
2,2-Dimethyltetralone, [1'-C-13(1); 1'-H-2(3)]	2002	45	11	917-926
2,2-Dimethyltetralone, [1'-C-13(1); 1',1''-H-2(6)]	2002	45	11	917-926
2,2-Dimethyltetralone, [1',1''-C-13(2)]	2002	45	11	917-926
2,2-Dimethyltetralone, [1',1''-C-13(2); 1'-H-2(3)]	2002	45	11	917-926
2,2-Dimethyltetralone, [1',1''-C-13(2); 1',1''-H-2(6)]	2002	45	11	917-926
2,2-Dimethyltetralone, [1',1''-H-2(6)]	2002	45	11	917-926
2,2-Dimethyltetralone, [1'-H-2(3)]	2002	45	11	917-926
2,2-Dimethyltetralone, [1'-C-13(1); 1''-H-2(3)]	2002	45	11	917-926
1,3-Diphenylprop-2-enone, [2,2'-H-2(2)]	2003	46	6	531-537
DR4446, [C-11]	2002	45	10	857-866
DMP 852, [C-14] or [H-3]	2003	46	4	353-363

E

(<i>S</i>)-4-(2,3-Epoxypropyloxy)-indole, [2-C-14]	2002	45	13	1143-1152
Ethyl [3-C-14]-acetoacetate	2002	45	10	823-829
1-Ethyl-6-fluoro-1,4-dihydro-7-(4-methyl-1-piperazinyl)-4-oxoquinoline-3-carboxylic acid, [F-18]	2003	46	8	715-727
1-Ethyl-6-fluoro-1,4-dihydro-7-(1-piperazinyl)-4-oxoquinoline-3-carboxylic acid, [F-18]	2003	46	8	715-727

Compound	Year	Vol	Part	Pages
F				
<i>S</i> -Farnesylcysteine, [35- <i>S</i>]- <i>N</i> -methanesulfonyl-FK960, [F-18]	2003	46	1	29–54
4-Fluoroaniline. [F-18], from 1,4-dinitrobenzene	2002	45	14	1219–1238
4-Fluorobenzaldehyde. [F-18], prep. of, and reaction with alkenes	2002	45	12	1045–1053
4-Fluorobenzoic acid, [F-18], and ethyl ester	2002	45	14	1219–1228
2-Fluoroethyl bromide, [F-18]	2003	46	4	379–388
2-Fluoroethyl bromide, [F-18], NaI as catalyst in SN reactions of	2003	46	6	587–598
5-(2-Fluoroethyl)-2'-deoxyuridine, [F-18]	2003	46	5	421–439
3-(<i>N</i> -{2-Fluoroethyl}- <i>N</i> -ethylamino)-6-diethylamino-acridine, [F-18], <i>also</i> BF-108	2003	46	8	765–772
2-Fluoroethyl (<i>R</i>)-1-(1-phenylethyl)-1 <i>H</i> -imidazole-5-carboxylate, [F-18]	2003	46	4	379–388
2-Fluoroethyl triflate, [F-18], from FCH ₂ CH ₂ Br	2003	46	6	587–598
<i>O</i> -(2-Fluoroethyl)- <i>L</i> -tyrosine, automated commercial prep.	2003	46	7	661–668
(2 <i>R</i>)-2-[[4-(6-Fluorohex-1-ynyl)phenyl]sulfonylamino]-3-(1 <i>H</i> -indol-3-yl)propionic acid, [F-18]	2002	45	11	975–986
(2 <i>R</i>)-2-[[4-(6-Fluorohex-1-ynyl)phenyl]sulfonylamino]-3-methylbutyric acid, [F-18]	2002	45	11	975–986
(2 <i>R</i>)-2-[[4-(6-Fluorohex-1-ynyl)phenyl]sulfonylamino]-4-methylsulfanylbutyric acid, [F-18]	2002	45	11	975–986
4-Fluoroiodobenzene, [F-18]	2003	46	8	699–713
Fluoromethyl triflate, [F-18]	2003	46	6	555–566
<i>O</i> -(Fluoromethyl)- <i>L</i> -tyrosine, [F-18]	2003	46	6	555–566
2-Fluoronitrobenzene, [F-18], various synth. routes	2002	45	13	1103–1113
<i>S</i> -(4-Fluorophenyl)cysteine, [F-18]	2002	45	14	1229–1238
1-(4-Fluorophenyl)-heptan-1-one, [F-18]	2002	45	12	1045–1053
4-Fluorophenyl ketones, [F-18], synth.	2002	45	12	1045–1053
1-(4-Fluorophenyl)-4-phenoxybutan-1-one, [F-18]	2002	45	12	1045–1053
1-(4-Fluorophenyl)-4-phenylbutan-1-one, [F-18]	2002	45	12	1045–1053
5-(2-Fluorovinyl)-2'-deoxyuridine, [F-18]	2003	46	5	421–439
Formaldehyde, [C-11]	2003	46	5	449–458
2-Formamidoimidazole, [C-13(2); N-15(3)]	2002	45	12	1055–1064
G				
Galantamine, [H-3], [C-13] <i>or</i> [C-14]	2002	45	10	841–855
Galantamine, [1- <i>H</i> -3(1)]	2002	45	10	841–855
6-(β- <i>D</i> -Glucopyranuronosyl)-17-methylmorphinan, [18- <i>H</i> -2(3)]	2002	45	13	1153–1158
Glyoxal, [1,2- <i>H</i> -2(2)]	2003	46	3	243–253
H				
(-)-[4a <i>S</i> -(4aα,6β,8a*)]-4a,5,9,10,11,12-Hexahydro-3-methoxy-11-([C-14]-methyl)-6 <i>H</i> -benzofuro-[3a,3,2-ef[2]-benzazepin-6-ol, <i>see</i> <i>Methylgalantamine</i>	2002	45	10	841–855

Compound	Year	Vol	Part	Pages
(-)-[4a <i>S</i> -(4 <i>α</i> ,6 <i>β</i> ,8 <i>α</i> *)]-4 <i>a</i> ,5,9,10,11,12-Hexahydro-3-([C-14]-methoxy)-11-methyl-6 <i>H</i> -benzofuro-[3 <i>a</i> ,3,2-ef[2]-benzazepin-6-ol, <i>see Methylgalantamine</i>	2002	45	10	841–855
(-)-[4a <i>S</i> -(4 <i>α</i> ,6 <i>β</i> ,8 <i>α</i> *)]-4 <i>a</i> ,5,9,10,11,12-Hexahydro-3-([C-13;H-2(3)]methoxy)-11-methyl-6 <i>H</i> -benzofuro-[3 <i>a</i> ,3,2-ef[2]-benzazepin-6-ol, <i>see Methylgalantamine</i>	2002	45	10	841–855
(-)-[4a <i>S</i> -(4 <i>α</i> ,6 <i>β</i> ,8 <i>α</i> *)]-4 <i>a</i> ,5,9,10,11,12-Hexahydro-3-methoxy-11-([C-14]-methyl)-6 <i>H</i> -benzofuro-[3 <i>a</i> ,3,2-ef[2]-benzazepin-6-ol, [1-H-3(1)], <i>see Methylgalantamine</i>	2002	45	10	841–855
Holmium-166, complex with DOTA	2003	46	3	197–209
Hydroxyacetone, [1,2,3-C-13(3)]	2003	46	9	793–798
(-)-(<i>R</i>)-2-(4-{6-Hydroxy-[4-C-14]-chromen-2-yl-methyl)-amino}butyl)-1,1-dioxo-1,2-benzisothiazole-3(2 <i>H</i>)-one, <i>also</i> 6-Hydroxyrepinotan	2002	45	13	1115–1132
4-Hydroxyindole, [2-C-14(1)]	2002	45	13	1143–1152
3-Hydroxy-4-([H-2(3)]-methoxy)-phenylalanine	2003	46	5	389–394
4-Hydroxy-3-([H-2(3)]-methoxy)-phenylalanine	2003	46	5	389–394
2-Hydroxy-3-(1-methylethyl)pyrazine, [5,6-H-2(2)]	2003	46	3	243–253
6-Hydroxy-17-methylmorphinan, [18-H-2(3)]	2002	45	13	1153–1158
2-Hydroxy-3-(2-methylpropyl)pyrazine, [5,6-H-2(2)]	2003	46	3	243–253
2-Hydroxynaphtha-1,4-quinone, [Ar-C-14] <i>also</i> Lawsone	2002	45	14	1265–1268
6-Hydroxy-repinotan hydrochloride, [4-chromane-C-14(1)]	2002	45	13	1115–1132
5-Hydroxy-L-tryptophan, [1-C-14]	2003	46	5	441–447
5-Hydroxy-L-tryptophan, [α-H-2] and [α-H-3]	2003	46	8	691–698
I				
IgG, [I-125]-labelled	2002	45	11	927–934
(<i>S</i>)-2-{4-[2-(3-{[2-C-14]-Indol-4-yloxy}-2-hydroxypropyl-amine)-2-methylpropyl]phenoxy}pyridine-5-carboxamide, <i>also</i> LY368842, as the glycolate	2002	45	13	1143–1152
2- <i>O</i> - and 3- <i>O</i> -Iodobenzyl-L-ascorbic acid, [I-125]	2003	46	8	737–750
2-Iodo- <i>para</i> -carborane, [I-125] exchange	2003	46	7	623–631
<i>N</i> -{2-(2-Iodo-5-fluorophenyl)-(1 <i>R</i> ,2 <i>R</i>)-cyclopropylmethyl}-butanamide, [I-125]	2002	45	11	987–994
<i>N</i> -{2-(2-Iodo-5-methoxyphenyl)-(1 <i>R</i> ,2 <i>R</i>)-cyclopropyl-methyl}butanamide, [I-125]	2002	45	11	987–994
4-Iodo- <i>N</i> -(4-(4-(2-methoxyphenyl)-piperazin-1-yl)-butyl)-benzamide, [I-123]	2003	46	4	297–305
4-Iodo- <i>N</i> -(4-(4-(2-methoxyphenyl)-piperazin-1-yl)-butyl)-benzamide, [I-123]	2003	46	5	411–419
Iodo-NN2211, [I-125] and [I-127]	2003	46	6	499–510
6- <i>O</i> -m-Iodophenyl-L-ascorbic acid, [I-125]	2003	46	8	737–750

Compound	Year	Vol	Part	Pages
<i>N</i> -(<i>E</i> -3-Iodoprop-2-enyl)-2 α -iminomethyl-3 β -(3,4-dichlorophenyl)-nortropane, [I-123], <i>also</i> KUC-25019	2002	45	12	1011–1017
<i>N</i> -(<i>E</i> -3-Iodoprop-2-enyl)-2 β -carbomethoxy-3 β -(4'-tolyl)-nortropane, [I-123], <i>also</i> PE2I	2002	45	12	1019–1028
<i>O</i> -Isopropyl ([C-14]-methyl)phosphonofluoridate (Sarin)	2003	46	7	599–604
J				
JTP-20604, [C-13]	2003	46	7	605–611
JTT-501, [C-13]	2003	46	7	605–611
K				
KUC-25019, [I-123]	2002	45	12	1011–1017
L				
Lawson, [Ar-C-14]	2002	45	14	1265–1268
Leflunomide, [C-13(4)]	2003	46	7	613–622
M				
Mecillinam, [H-3]	2003	46	8	773–779
2-(Methoxy-[H-2(3)])-3-(1-methylethyl)pyrazine, [5,6-H-2(2)]	2003	46	3	243–253
2-(Methoxy-[H-2(3)])-3-(2-methylpropyl)-pyrazine, [5,6-H-2(2)]	2003	46	3	243–253
6-Methoxy-17-methylmorphinan, [18-H-2(3)]	2002	45	13	1153–1158
2{[C-13(1); H-2(2); N-15(1)]-Methylamino}-{[2-C-13(1); 1,3-N-15(2)]}-imidazole hydrochloride	2002	45	12	1055–1064
2{[C-13(1); H-2(2); N-15(1)]-Methylamino}-{[2-C-13(1); 1-N-15(1); 4-H-2(1)]}-imidazole hydrochloride	2002	45	12	1055–1064
2-Methylbenzosuberone, [1'-C-13]	2002	45	11	917–926
2-Methylbenzosuberone, [1'-C-13; 2-H-2(1)]	2002	45	11	917–926
2-Methylbenzosuberone, [CH ₃ -H-2(3)], [CH ₃ -C-13] and/or [2-H-2(1)]	2002	46	6	515–530
<i>N</i> -([C-14]-Methyl)galantamine	2002	45	10	841–855
<i>O</i> -([C-14]-Methyl)galantamine	2002	45	10	841–855
<i>O</i> -([C-13; H-2(3)]-Methyl)galantamine	2002	45	10	841–855
2-Methylindanone, [CH ₃ -H-2(3)], [CH ₃ -C-13] and/or [2-H-2(1)]	2002	46	6	515–530
Methyl iodide, [C-11]	2002	45	10	803–811
Methyl iodide, [C-11]	2002	45	10	857–866
Methyl iodide, [C-11]	2002	45	14	1199–1207
Methyl iodide, [C-11]	2003	46	1	55–65
Methyl iodide, [C-11]	2003	46	3	255–261
Methyl iodide, [C-11]	2003	46	3	263–272
Methyl iodide, [C-11]	2003	46	4	333–342
Methyl iodide, [C-13, H-2(3)]	2003	46	4	291–296
{4-[C-11]-Methyl}metaraminol	2003	46	1	55–65
(2 <i>R</i>)-3-Methyl-2-{{4-({4-(methoxy[C-11])benzoyl}amino)-benzenesulfonyl}amino}butanoic acid	2003	46	6	539–553

Compound	Year	Vol	Part	Pages
(10-[C-11]-Methyl)-3-(6-nitro-2-quinolinyl)-3,10-diazabicyclo-[4.3.1]-decane	2003	46	9	873–882
4-{2-(5-Methyl-2-phenyl-4-oxazolyl)ethoxy}-[ring-C-13(6)]-benzaldehyde	2003	46	7	605–611
(±)-(RS)-4-{4-[2-(5-Methyl-2-phenyl-4-oxazolyl)ethoxy]-[ring-C-13(6)]-benzyl}isoxazolidine-3,5-dione	2003	46	7	605–611
<i>R</i> -(-)- <i>N</i> -Methyl- <i>N</i> -2-propynyl-1-phenyl-2-propylamine, <i>see</i> L-Deprenyl, <i>R</i> -(-)-Deprenyl	2002	45	10	803–811
1-Methyl-2a-[4-(4,5,6,7-tetrahydrothieno[3,2- <i>c</i>]pyridin-5-yl)butyl]-2a,3,4,5-tetrahydro-1 <i>H</i> -benz[<i>cd</i>]indole-2-one, [C-11], <i>see also</i> DR4446	2002	45	10	857–866
2-Methyltetralone, [H-2]-incorporation into,	2002	45	11	965–973
2-Methyltetralone, [CH ₃ -H-2(3)], [CH ₃ -C-13] and/or [2-H-2(1)]	2002	46	6	515–530
3-(Methyl-[C-11])-thiophene	2003	46	3	255–261
Methyl triflate, [C-11]	2002	45	10	803–811
Methyl triflate, [C-11]	2002	45	14	1199–1207
Methyl triflate, [C-11]	2002	45	14	1239–1252
Methyl triflate, [C-11]	2003	46	6	555–566
5-Methyl- <i>N</i> -(4-trifluoromethylphenyl)-4-isoxazolone-carboxamide, [C-13(4)]	2003	46	7	613–622
<i>O</i> -[(Methyl-[C-13])-L-tyrosine	2003	46	6	555–566
Microwave-enhanced deuteration	2003	46	6	567–574
N				
Nicotinamide, [O-18]	2002	45	12	1005–1010
<i>N</i> -Nitrosoanatabine, [5-H-3]	2002	45	13	1133–1141
1-Nitroso-1,2,3,4-tetrahydro-2,3'-bipyridyl	2002	45	13	1133–1141
NN 2211, [C-14]	2003	46	6	499–510
NNC 61-4655, [H-3 or C-14]	2003	46	9	861–871
NS 2495, [C-11]	2003	46	9	873–882
Norfloxacin, [F-18]	2003	46	8	715–727
O				
Octanoic acid, [1-C-13(1)] and K salt	2002	45	13	1091–1096
4-Oxo-{{4H-C-14}-chromane}-2-carboxylic acid, Me ester	2002	45	13	1115–1132
4-Oxo-{{U-C-14}-chromane}-2-carboxylic acid	2002	45	13	1115–1132
P				
[P-32]-labelled purine derivatives	2002	45	13	1097–1102
PE2I, [I-123]	2002	45	12	1019–1028
Pefloxacin, [F-18]	2003	46	8	715–727
1,2,3,4,6-Penta- <i>O</i> -galloyl-{{U-C-14}-D-glucopyranose}	2003	46	1	99–105
PET-tracers, review of available	2003	46	1	1–27
(<i>S</i>)-3-(4-([2-C-14]-2-(Phenoxazin-10-yl)ethoxy)-phenyl)-2-ethoxypropanoic acid, <i>also</i> Ragaglitsazar	2003	46	5	475–488

Compound	Year	Vol	Part	Pages
(<i>S</i>)-3-(4-(2-((6,14-H-3(2))-Phenoxazin-10-yl)ethoxy)-phenyl)-2-ethoxypropanoic acid, <i>also</i> Ragaglitsazar	2003	46	5	475–488
(<i>S</i>)-3-(4-(2-(Phenoxazin-10-yl)ethoxy)phenyl)-2-ethoxypropanoic acid, [2,3-H-3(2)], <i>also</i> Ragaglitsazar	2003	46	5	475–488
2-[U-C-14]-Phenoxysuccinic acid	2002	45	13	1115–1132
1-Phenylbutan-3-one, [1,2-H-2(2)]	2003	46	6	531–537
<i>N</i> -{(1 <i>R</i>)-1-Phenylethyl}-(2 <i>R</i> ,2 <i>S</i>)[U-C-14]-chromane-2-carboxamide	2002	45	13	1115–1132
(2 <i>R</i> ,2 <i>S</i>)-2-{ <i>N</i> -[(1 <i>R</i>)-1-Phenylethyl]}aminomethyl-[U-C-14]-chromane, <i>and</i> (2 <i>R</i>)-enantiomer	2002	45	13	1115–1132
3-Phenylpropionic acid, [2,3-H-2(2)], ethyl ester	2003	46	6	531–537
<i>N</i> -(Piperidin-1-yl)-5-(4-methoxyphenyl)-1-(2-chloro-phenyl)-4-fluoro-1 <i>H</i> -pyrazole-3-carboxamide, [F-18]	2003	46	1	93–98
PNU-141962, [H-2(3)]	2002	45	14	1209–1218
PNU-166196A, [H-2(4)]	2002	45	11	899–909
PNU-166196A, [C-14]	2002	45	11	899–909
17 α -(3-[C-11]-Prop-1-yn-1-yl)-3-methoxy-3,17 β -estradiol	2003	46	4	333–342
3-([2-C-14]-1-Pyrrolin-2-yl)-pyridine, <i>also</i> Myosmine	2003	46	5	395–400
Q				
R				
Repinotan hydrochloride, [U-C-14] and [4-chromane-C-14(1)]	2002	45	13	1115–1132
S				
Sarin, [C-14]	2003	46	7	599–604
SHPP, [I-124]	2002	45	12	1077–1090
<i>N</i> -Succinimidyl 4-iodobenzoate, [I-125]	2002	45	11	927–934
<i>N</i> -Succinimidyl 3-(4-hydroxy-5-iodophenyl)propionate, [I-124] <i>also</i> SHPP, [I-124]	2002	45	12	1077–1090
Sulforaphane, [C-14]	2003	46	9	851–859
T				
[Tc-99 m], complex with 2-methoxyisobutylisonitrile	2002	45	12	1029–1043
[Tc-99 m] complexes with 4-((1,4,8,11-cyclotetradecyl)-methyl)-benzoic acid (CPTA)	2003	46	2	175–186
[Tc-99 m], complexes with MAG ₃ derivatives	2003	46	1	73–84
[Tc-99 m] complexes with 4-[1,4,8,11-tetraazacyclotetradec-1-yl-methyl]benzoic acid conjugates with oligonucleotides	2003	46	2	175–186
[Tc-99 m] dithiobenzoate derivatives	2003	46	4	319–331
[Tc-99 m], EDDA-HYNIC-D-Phe ¹ , Tyr ³ octreotide	2003	46	4	307–318
[Tc-99 m]-Stannous fluoride colloid labelled leucocytes	2003	46	8	751–763

Compound	Year	Vol	Part	Pages
[Tc-99 m]- <i>S,S'</i> -bis-trityl- <i>N</i> -BOC-1,2-ethylene-dicysteamine—2-nitroimidazole conjugate	2003	46	6	575–585
[Tc-99 m]-tricarboxyl-mebrofenin	2003	46	7	633–644
1,4,7,10-Tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA)	2003	46	3	197–209
2,3,5,6-Tetrafluorophenyl 2-(2-nitroimidazol-1-yl) acetate	2003	46	6	511–513
(-)- Δ^9 -Tetrahydrocannabinols, [H-2] (n-pentyl side-chain)]	2002	45	12	1065–1076
Thiourea, [C-13(1); N-15(2)]	2002	45	12	1055–1064
1-[4-(<i>m</i> -Tolyl)amino-6-quinazoliny]-3-([C-14]-methyl)-triazene	2003	46	8	729–735
3,4,5-Trimethoxybenzyl alcohol, [7-H-2(2)]	2002	45	10	831–839
3,4,5-Trimethoxybenzyl bromide, [7-H-2(2)]	2002	45	10	831–839
3,4,5-Trimethoxytoluene, [7-H-2(3)]	2002	45	10	831–839
L-Tryptophan, [1-C-14]	2003	46	5	441–447
L-Tryptophan, [α -H-2] and [α -H-3]	2003	46	8	691–698
	U			
	V			
(<i>R</i>)- and (<i>S</i>)-Verapamil, [<i>N</i> -C-11]	2002	45	14	1199–1207
	W			
WIN 55212-2, [5,7-naphthyl-H-3(2)]	2003	46	1	67–71
	X			
	Y			
	Z			
Zaleplon, [H-3]	2002	45	11	911–915